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Summary
 
Rats of the PVG.RT1
 
u
 
 strain develop autoimmune diabetes when thymectomized at 6 wk of
age and are rendered relatively lymphopenic by a cumulative dose of 1,000 rads 
 
137
 
Cs 
 
g
 
-irradi-
ation given in four split doses. Previous studies have shown that the disease is prevented by the
intravenous injection of 5 
 
3
 
 10
 
6
 
 CD4
 
1
 
 CD45RC
 
2
 
 TCR
 
ab
 
1
 
 RT6
 
1
 
 peripheral T cells from
normal syngeneic donors. These cells have a memory phenotype and are presumably primed to
some extrathymic antigen. However, we now report that the CD4
 
1
 
 CD8
 
2
 
 population of ma-
ture thymocytes is a very potent source of cells, with the capacity to prevent diabetes in our
lymphopenic animals. As few as 6 
 
3
 
 10
 
5
 
 of these cells protect 
 
z
 
50% of recipients and the level
of protection increases with cell dose. It appears that one characteristic of the intrathymic selec-
tion of the T cell repertoire is the generation of cells that regulate the autoimmune potential of
peripheral T cells that have been neither clonally deleted intrathymically nor rendered irrevers-
ibly anergic in the periphery.
 
D
 
iscussions of the mechanisms whereby T cell responses
are made to foreign antigens but not to self usually
classify autoantigens into two groups, those that are in-
trathymic and those that are extrathymic. There is compel-
ling evidence that for those self-antigens expressed within the
thymus, the corresponding T cells are clonally deleted (1)
at a stage in their development at which encounter with
specific antigen induces cell death. While this mode of tol-
erance induction is conceptually attractive as far as intrathy-
mic self-antigens are concerned, it does not address the
question as to how the immune system achieves tolerance
to tissue-specific peripheral self-antigens. The processes
that mediate tolerance to these are regarded as occurring
solely extrathymically and depend on a distinction being
made between the way that self-antigens and foreign anti-
gens are presented to peripheral T cells. Whereas foreign
antigens are presented by appropriate antigen-presenting
cells that induce specific T cell activation and, conse-
quently, adaptive immunity, self-antigens are believed to
be presented by cells that lack the relevant costimulatory
molecules (2, 3) with the result that the potentially autore-
active T cells are either rendered anergic (2) or simply fail
to respond at all, a process known as clonal indifference (4).
A common feature of all of these mechanisms is that they
are all passive in the sense that they depend either on the
intrathymic autolysis of autoreactive T cells at a crucial de-
velopmental stage or on processes that extrathymically induce
intrinsic nonresponsiveness of cells that are not deleted.
However there is a considerable amount of experimental
data that casts doubt on the completeness of the forgoing
explanation of self-tolerance. The data support the view
that self-tolerance to at least some autoantigens also re-
quires the presence of T cells, which play an active role in
suppressing the autoreactive potential of cells that have nei-
ther been clonally deleted nor become anergic (5–11, re-
viewed in 12). These experiments, while all compatible
with the view that the prevention of autoimmune re-
sponses requires the active participation of T cells that play
some protective or regulatory role, raise a number of ques-
tions with regard to the way such a population of regula-
tory T cells (hereafter abbreviated to T
 
reg
 
) are generated. In
an earlier series of experiments, we showed that a very high
incidence of autoimmune diabetes developed in rats that
were thymectomized as young adults and then made lym-
phopenic by sublethal 
 
g
 
-irradiation (9). Most of the data
reported in that paper concerned the characterization of the
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subset of CD4
 
1
 
 peripheral T cells that, on transfer from
normal syngeneic donors, prevented the development of
the disease. However, in a small study involving a few ani-
mals it was also found that the transfer of CD4
 
1
 
CD8
 
2
 
 
 
thy-
mocytes was similarly protective. We now report the re-
sults of more extensive experiments, in which a comparison
has been made between the number of CD4
 
1
 
CD8
 
2
 
 thy-
mocytes and of peripheral CD4
 
1
 
 T cells required to achieve
protection from diabetes. The data show that the CD4
 
1
 
CD8
 
2
 
thymocyte subset is particularly potent in this comparison.
Consequently, the results are not compatible with the con-
cept that the protective subset of peripheral cells is gener-
ated by an extrathymic antigen-driven clonal expansion of
T
 
reg
 
 from intrathymic precursors present at low frequency.
Rather, the selection of this regulatory subset is an in-
trathymic event. Possible mechanisms are discussed.
 
Materials and Methods
 
Animals and Induction of Diabetes.
 
6- to 12-wk-old PVG.RT1
 
c
 
or PVG.RT1
 
u
 
 strain rats of either sex were used, and these were
bred in the specific pathogen-free unit of the Medical Research
Council Cellular Immunology Unit (Oxford, UK). To induce
diabetes, PVG.RT1
 
u
 
 rats were thymectomized at 6 wk of age
and, starting 2 wk later, were given four equal doses of 250 rads
 
137
 
Cs 
 
g
 
-irradiation at 2-wk intervals. Over the ensuing 10–12 wk,
virtually all the males (exclusively used in this study) and 70% of
the females developed autoimmune diabetes (9). Rats were peri-
odically bled and blood glucose levels assayed using a glucose
hexokinase (HK) reagent (Sigma Diagnostics, Poole, UK). Rats
were classed diabetic if weight loss was associated with blood glu-
cose levels in excess of 400 mg/dL.
 
mAbs.
 
The mouse monoclonal antibodies (mAbs) used in these
studies were as follows: W3/13 (anti-rat Leukosialin) (13); W3/
25 (anti-rat CD4) (13); OX22 (anti-rat exon C of CD45) (14,
15); OX32 (anti-rat exon C of CD45, noncompetitive with
OX22) (14, 16); OX12 (anti-rat Ig
 
k
 
 chain) (17); OX-6 (anti-rat
MHC class II) (18); OX-8 (anti-rat CD8) (19); OX-21 (anti-human
C3b inactivator) (20). Rabbit anti–mouse Ig (RAM–Ig) and
FITC-conjugated Fab fragments of RAM Ig (RAM–Fab–FITC)
were prepared by S. Simmonds in this laboratory and PE-conju-
gated rabbit anti–mouse Ig (RAM–PE) was from Serotec (Kidling-
ton, UK). OX12 IgG was iodinated (
 
125
 
I) as already described (21).
 
Isolation of T Cells and Thymocyte Subpopulations.
 
Rat thoracic duct
lymphocytes (TDLs) were obtained by cannulation of the duct
(22). Cells were collected at 4
 
8
 
C overnight into flasks containing
PBS and 20 U/ml heparin. Thymocytes were prepared by the
pressing of thymus fragments through a stainless steel mesh, filter-
ing off the debris through a cotton wool or lens tissue filter, and
washing the single cell suspension so obtained in ice-cold cell-
handling medium.
Rat lymphocyte populations were negatively selected from
TDLs or thymocytes using a rosetting technique as described
elsewhere (23). CD4
 
1
 
CD8
 
2
 
 thymocytes, together with small
numbers of CD4
 
2
 
CD8
 
2
 
 cells were isolated by depletion of
CD8
 
1
 
 cells using the mAb OX8. B cells were obtained from
TDLs by depleting T cells using W3/13 mAb. CD4
 
1
 
 T cells
were isolated by depletion of B cells and CD8
 
1
 
 T cells using the
mAbs OX12, OX8, and OX6. To obtain CD4
 
1
 
CD45RC
 
2
 
 T
cells TDLs were depleted using the mAbs OX22, OX32, and
OX8. The purity of all isolated cells was analyzed on a FACScan
 
Ò
 
(Becton Dickinson, Palo Alto, CA) by labeling pre- and postde-
pletion samples with RAM–PE. The percentage of contaminated
cells was between 0.5 and 5%.
 
In Vivo B Cell Help Assay.
 
Primed B and T cells were puri-
fied from the TDLs of PVG.RT1
 
c
 
 rats immunized intraperito-
neally with 1 ml of 10% SRBC 6–10 wk previously. Irradiated
(800 rads, 24 h previously) syngeneic recipient rats were reconsti-
tuted with purified B cells (3 
 
3
 
 10
 
7
 
) and 1ml of 10% SRBC. Dif-
ferent groups of rats also received one of three cells doses (20, 10,
or 5 
 
3
 
 10
 
6
 
 cells) of either CD4
 
1
 
CD8
 
2
 
 thymocytes or primed pe-
ripheral CD4
 
1
 
 T cells. Control rats received no additional cells.
Sera from these animals were taken after 7 d, heat-inactivated,
and assayed for anti-SRBC antibody using a radioimmunoassay as
already described (24). In brief, 50 
 
m
 
l of 10
 
9
 
 SRBC/ml were
plated out into the wells of a microtiter plate. SRBC were incu-
bated with diluted sera in triplicate for 2 h at 4
 
8
 
C, followed by
four washes with PBS containing 0.05% BSA, and a further 2 h
incubation with 
 
125
 
I–OX12 IgG (100 ng/ml) also followed by
four washes. The SRBC were harvested and counted in a Rack-
gamma counter (1261 MULTIGAMMA, Pharmacia LKB, Upp-
sala, Sweden) using 15 s counts/tube.
 
Results
 
Previous studies in our laboratory have demonstrated
that PVG.RT1
 
u
 
 rats, a normal strain with no tendency to
develop autoimmunity, spontaneously develop fatal insu-
lin-dependent diabetes by 8–10 wk after the final dose of
irradiation (9) when thymectomized at 6 wk of age and
then subjected to four doses of 250 rads 
 
137
 
Cs 
 
g
 
-irradiation
at 2-wk intervals. The disease can be completely prevented
by the intravenous injection of a particular subset of pe-
ripheral CD4
 
1
 
 T cells from syngeneic normal donors. The
phenotype of the disease-preventing T cells has been deter-
mined: the cells are CD4
 
1
 
 CD45RC
 
2
 
 TCR 
 
ab
 
1
 
 RT6
 
1
 
(9) and a dose of 5 
 
3
 
 10
 
6
 
 cells protects 100% of recipients.
The most direct interpretation of these findings is that normal
PVG.RT1
 
u
 
 rats have T cells that have a diabetogenic po-
tential, but that this potential is only revealed by a radia-
tion-induced lymphopenia that abrogates the protective ac-
tion of the CD4
 
1
 
 CD45RC
 
2
 
 TCR 
 
ab
 
1
 
 RT6
 
1
 
 regulatory
T cells.
Given that the peripheral CD4
 
1
 
 T cell subset that pre-
vents diabetes has a primed T cell phenotype, and that in-
sulin-dependent diabetes is a tissue-specific autoimmune
disease, it was anticipated that the priming of the protective
T cells took place in the periphery, possibly in the lymph
nodes draining the pancreas. Such a hypothesis would pre-
dict that CD4
 
1
 
CD8
 
2
 
 thymocytes, being a naive popula-
tion, would be far less potent at controlling the diabetes
than the clonally expanded peripheral T cells would be.
However, this prediction was not confirmed by experi-
ment. Assays of the ability of twofold decreasing doses of
CD4
 
1
 
CD8
 
2
 
 thymocytes to protect prediabetic recipients
from disease produced a very flat dose/response curve.
While 5 
 
3
 
 10
 
6
 
 of these cells protected 11 of 15 recipients,
significant protection was still observed at a dose eight
times lower than this (Fig. 1). In contrast, when 5 
 
3
 
 10
 
6
 
CD4
 
1
 
CD45RC
 
2
 
 peripheral cells were transferred into 
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prediabetic recipients, all animals (23/23) were protected
from disease, but at one-half this cell dose, protection was
almost completely lost, with six of eight recipients becom-
ing diabetic. A further twofold reduction in the dose of do-
nor cells failed to protect any recipients (Fig. 1).
To exclude the possibility that thymocytes were gener-
ally more potent at mediating T cell functions when trans-
ferred into lymphopenic recipients, we compared, in an
adoptive transfer system, the ability of CD4
 
1
 
CD8
 
2
 
 thy-
mocytes and SRBC-primed CD4
 
1
 
 peripheral T cells to
provide primed B cells with help to produce specific anti-
body. PVG.RT1
 
c
 
 rats were injected with 1 ml of 10%
SRBC and cannulated between 6 and 8 wk after immuni-
zation. Primed B cells and CD4
 
1
 
 T cells were purified
from the TDLs of these animals and 3 
 
3
 
 10
 
7
 
 B cells were
injected into irradiated (800 rads) syngeneic recipients with
further antigen (1 ml of 10% SRBC) and different doses of
CD4
 
1
 
 primed T cells or CD4
 
1
 
CD8
 
2
 
 thymocytes from
normal PVG.RT1
 
c
 
 donors. Sera were taken from these an-
imals 1 wk later and assayed for antibodies specific for
SRBC using a radioimmunoassay. The data in Fig. 2 show
that in contrast with their potency in the prevention of dia-
 
betes, the CD4
 
1
 
CD8
 
2
 
 thymocytes were less active than
CD4
 
1
 
 primed peripheral T cells in providing B cells with
help for antibody production. Repeating this experiment
using unprimed rather than primed peripheral CD4
 
1
 
 T
cells showed that these too were more potent at providing
B cell help (data not shown).
 
Discussion
 
Taken together, the foregoing observations are not com-
patible with the concept that the peripheral T cells that
prevent diabetes are generated by an antigen-driven expan-
sion of naive T cells derived from thymocyte precursors
that exist at a low frequency. While in principle it is possi-
ble that the thymocyte transfer experiments are artifactual,
in that there is no direct evidence that the regulatory thy-
mocytes we assay normally leave the thymus, we have
shown that the cells express the 
 
L
 
-selectin homing receptor
(25), and it is difficult to conceive of an intrathymic role for
such expression. Instead, it seems more likely that they are
the precursors of the peripheral T cells that prevent diabe-
tes on adoptive transfer.
Figure 2. Naive CD41CD82 thymocytes are less potent in providing
in vivo B cell help than primed peripheral CD41 T cells. Primed CD41
T cells and primed B cells were negatively selected from TDLs from
PVG.RT1c rats primed with 108 SRBC 4–9 wk before cannulation. Na-
ive CD41CD82 thymocytes were negatively selected from thymus of
normal PVG.RT1c rats by rosette depletion as described in Materials and
Methods. Syngeneic recipients were given 800 rads and injected i.v. 1 d
later with 108 SRBC, 3 3 107 SRBC-primed B cells and either three dif-
ferent doses of SRBC-primed CD41 peripheral T cells or three different
doses of naive CD41CD82 thymocytes. The controls were given 108
SRBC and 3 3 107 SRBC-primed B cells. The recipients were bled 7 d
later and the anti-SRBC antibody titers determined by radioimmunoas-
say. The results are expressed in arbitrary units made by comparison with
a pool of sera from rats immunized with SRBC.
Figure 1. CD41CD82 thymocytes are more potent than peripheral
CD41CD45RC2 T cells in protecting from diabetes. T cells subsets were
negatively selected from TDLs or thymus from normal PVG.RT1u rats by
rosette depletion as described in Material and Methods. Three different
doses of CD41CD45RC2 peripheral T cells and five doses of CD41
CD82 thymocytes were injected i.v. into recipient groups of prediabetic
rats shortly after their last irradiation. Results are expressed as percentage
of animals that are protected from development of diabetes and are a
compilation of 10 individual experiments involving, with controls, a total
of 136 animals. Numbers in parenthesis represent the aggregate number of
animals in each group. The purity of isolated cells was .95%.2396 Thymus and Generation of Regulatory Cells
The antigen specificity of the regulatory cells is un-
known. In particular, it is not known whether they re-
spond to environmental antigens or to self, or even possibly
to both (26–28). However, in other experimental systems
allogeneic, or even xenogeneic, thymic epithelium trans-
plantation can give rise to the generation of regulatory T cells
that mediate dominant tolerance to antigens expressed on
the transplanted thymic epithelia (5, 6, 29). These data in-
dicate that the role played by the thymus in preventing pe-
ripheral immunity to intrathymic self-antigens is not readily
accounted for solely in terms of the generation of a T cell
repertoire that is clonally deleted for self and reactive to
non-self. Instead, the results would seem to require that
thymic epithelium facilitates the generation of T cells that
can actively control potentially autoreactive T cells. The
mRNA for several putatively tissue-specific self-antigens is
also expressed intrathymically (30), and this expression has
been found to occur in thymic epithelial cells (31, 32). It
has been shown that such mRNA can lead to gene expres-
sion in that a number of transgenes placed under promoters
that are nominally tissue specific have been shown to be
expressed intrathymically (32, 33). These observations may
bear on the question of the nature of the autoantigen in the
lymphopenia-induced diabetes that we study. It has been
shown that rats injected at birth with B chain peptides of
rat insulin are resistant to the subsequent induction of dia-
betes (31), and similar findings have been reported in the
NOD mouse (34, 35). These results, together with those
indicating the expression of the insulin gene in the thymus
(32, 36), suggest that insulin itself may be a target autoanti-
gen in insulin-dependent diabetes in rodents and, given the
results obtained with thymic epithelium transplantation re-
ferred to above, that at least some of the regulatory T cells
that protect lymphopenic rats from diabetes may be specific
for insulin.
Although CD41CD82 thymocytes could protect a sig-
nificant proportion of recipients from diabetes, even at a
dose of 6 3 105 cells, an inoculum almost ten times larger
failed to prevent disease in 100% of animals (Fig. 1). Similar
partial protection has also been observed by unfractionated
peripheral CD41 T cells (9), and the failure to protect all
recipients has been ascribed to an antagonistic effect of the
CD45RC1 subset in the inoculum on the protective action
of the CD45RC2 subset (9). This interpretation is sup-
ported by earlier observations that the CD45RC1 subset is
autoreactive (37). The data reported herein, on the gradual
increase in the level of protection against diabetes obtained
with increasing doses of CD41CD82 thymocytes, has been
analyzed theoretically using the assumption that a recipient
of such cells will be protected from diabetes if, by chance,
the inoculum contains more protective thymocytes than
diabetogenic thymocytes and, conversely, that disease will
develop if the opposite balance occurs. The ratio of the
sizes of these two antagonistic populations will be subject
to statistical variation and this fact forms the essential ele-
ment of the theoretical analysis. Details of this analysis are
presented in the Appendix but the findings are summarized
in Table 1. It will be seen that the theoretical prediction,
developed retrospectively, fits the data very well; in fact,
rather better than one might expect on the basis of a theory
that depends on statistically evaluated chance. The conclu-
sion that one can draw is that the analysis supports the hy-
pothesis but, by the very nature of such an approach, it
cannot be claimed to have proved it. Indeed, while the data
clearly support the conclusion that the thymus is a potent
source of CD41CD82 thymocytes with the capacity to
prevent diabetes on transfer into prediabetic recipients,
they do not exclude the possibility that the induction of the
regulatory phenotype is a postthymic event. The mathe-
matical model is equally applicable to such a hypothesis
but the physiological implications are quite different. As has
been reported, the peripheral CD41 cell that prevents dia-
betes on adoptive transfer has a primed phenotype, which
suggests that it has encountered its specific antigen after
leaving the thymus. This observation allows the possibility
that the inductive effect that gives rise to Treg occurs at a
postthymic stage of T cell differentiation and is compatible
with data that show, in other experimental systems, self-
tolerance requires the presence of the relevant autoantigen
in the periphery (38) as well as in the thymus (29, 39). Fur-
ther experiments are planned, specifically to test the predic-
tion of the theory that at very high thymocyte doses, pro-
tection from diabetes should be observed in almost all
recipients.
Irrespective of the nature of the underlying mechanism
that gives rise to the gradual increase in the level of protec-
tion from diabetes mediated by increasing doses of CD41
CD82 thymocytes, this observation provides a straightfor-
Table 1. Comparison of Experimental and Theoretical Results on 
Control of Diabetes by CD41CD82 Thymocytes
Thymocyte dose
Frequency of protected rats
Observed Calculated
3 106
5.0 11/15 11/15 (76%)
2.5 10/15 10/15 (69%)
1.25 7/12 8/12 (64%)
0.625 2/4 2/4 (59%)
25.0 ND 19/20 (94%)
The expected number of prediabetic rats protected from development
of diabetes by different doses of CD41CD82 thymocytes was calculated
using the statistical analysis detailed in the Appendix. The level of pro-
tection observed experimentally (Observed) is compared with predicted
values (Calculated). Percentages in parentheses indicate the calculated
frequencies of protection from diabetes. As indicated in the Appendix,
to calculate the percentage of rats protected from diabetes by thymocyte
transfer requires that values be ascribed to the frequency of diabetogenic
cells and regulatory ones. For example, if the frequency of diabetogenic
cells is assumed to be 1:32,000, then the frequency of regulatory cells is
just 8% greater than this. It is evident that the theoretical predictions fit
the experimental data only if the excess of regulatory cells over diabeto-
genic ones is small.2397 Saoudi et al. Brief Definitive Report
ward explanation for the induction of autoimmunity in mice
thymectomized within the first few days of life (40–42).
Our findings suggest that until the number of thymocytes
exported into the periphery reaches some critical number,
the regulatory mechanism that prevents autoimmunity is
not intact. Because the neonatal mouse is immunologically
immature, this critical number will not be attained until
some time in the postnatal period, and thymectomy during
this interval would be expected to cause a breakdown in
self-tolerance.
Appendix
A theoretical analysis of the data in Fig. 1 has been devel-
oped based on the hypothesis that the inocula of CD41CD82
thymocytes used to prevent diabetes contains two minority
populations, one that can cause the disease and one that can
prevent it. The further assumption is made that an inocu-
lum prevents diabetes if it contains more protective cells
than diabetogenic ones but that protection fails if the ratio
is reversed. Given that in any inoculum the numbers of
protective and diabetogenic cells will be subject to inde-
pendent statistical variation, it is possible to calculate the
probable proportion of recipients that will be protected
from diabetes at any cell dose. This proportion depends on
two numbers: the frequency of diabetogenic cells and the
ratio of this frequency to that of the regulatory cells. These
two variables are not independent, in that if a value for the
first is assumed then there is only one value of the second
that will give an agreement between theory and experi-
ment.
The essential feature of the analysis is illustrated by not-
ing that as the thymocyte dose increases, the standard devi-
ation in the number of diabetogenic cells, expressed as a
fraction of the total of these cells, decreases. Consequently,
if the frequency of regulatory (protective) thymocytes is
larger than that of the diabetogenic ones, the proportion of
recipients that are protected from diabetes will become
larger as the number of thymocytes injected is increased.
Formally, the proportion of animals that fail to be pro-
tected is given by the double integral:
where P is the proportion of rats that receive more diabetoge-
nic cells than regulatory ones; m is the mean number of dia-
betogenic CD41CD82 thymocytes in a given sample of these
cells, i.e., m 5 nq, where n 5 total number of CD41CD82
thymocytes in the sample and q is the frequency of diabeto-
genic cells among CD41CD82 thymocytes; (1 1 a) is the
ratio of regulatory cells to diabetogenic cells among CD41
CD82 thymocytes.
P 1
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m
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e
0
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2 m
----------------------------  
e
0
m
ò
m m 1 a + [] – ()  
2
–
2 m 1 a + ()
------------------------------------------------ dm dm · ·
· · · · =
We thank Steve Simmonds and Mike Puklavec for technical assistance and Phil Stumbles, Francisco
Ramirez, and Vicky Heath for discussion and assistance.
A. Saoudi is supported by a postdoctoral fellowship from the Wellcome Trust and from the Fondation pour
la Recherche Medicale of France. B. Seddon is supported by a Wellcome Trust Prize Studentship.
Address correspondence to Ben Seddon, MRC Cellular Immunology Unit, Sir William Dunn School of Pa-
thology, University of Oxford, Oxford OX1 3RE, UK.
Received for publication 8 July 1996 and in revised form 23 September 1996.
References
1. Kappler, J.W., M. Roehm, and P. Marrack. 1987. T cell tol-
erance by clonal elimination in the thymus. Cell. 49:273–280.
2. Mueller, D.L., M.K. Jenkins, and R.H. Schwartz. 1989.
Clonal expansion versus functional clonal inactivation: a co-
stimulatory signalling pathway determines the outcome of
T cell antigen receptor occupancy. Annu. Rev. Immunol. 7:
445–480.
3. Nickoloff, B.J., and L.A. Turka. 1994. Immunological func-
tions of non-professional antigen-presenting cells: new in-
sights from studies of T-cell interactions with keratinocytes.
Immunol. Today. 15:464–469.
4. Ohashi, P.S., S. Oehen, K. Buerki, H. Pircher, C.T. Ohashi,
B. Odermatt, B. Malissen, R.M. Zinkernagel, and H. Hen-
gartner. 1991. Ablation of "tolerance" and induction of dia-
betes by virus infection in viral antigen transgenic mice. Cell.
65:305–317.
5. Coutinho, A., J. Salaun, C. Corbel, A. Bandeira, and N. Le
Douarin. 1993. The role of thymic epithelium in the estab-
lishment of transplantation tolerance. Immunol. Rev. 133:
225–240.
6. Zamoyska, R., H. Waldmann, and P. Matzinger. 1989. Pe-
ripheral tolerance mechanisms prevent the development of
autoreactive T cells in chimeras grafted with two minor in-
compatible thymuses. Eur. J. Immunol. 19:111–117.
7. Fukuma, K., S. Sakaguchi, K. Kuribayashi, W.L. Chen, R.
Morishita, K. Sekita, H. Uchino, and T. Masuda. 1988. Im-
munologic and clinical studies on murine experimental au-
toimmune gastritis induced by neonatal thymectomy. Gastro-
enterology. 94:274–283.
8. Stumbles, P.A., and W.J. Penhale. 1993. IDDM in rats in-
duced by thymectomy and irradiation. Diabetes. 42:571–578.
9. Fowell, D., and D.W. Mason. 1993. Evidence that the T cell2398 Thymus and Generation of Regulatory Cells
repertoire of normal rats contains cells with the potential to
cause diabetes. Characterization of the CD41 T cell subset
that inhibits this autoimmune potential. J. Exp. Med. 177:
627–636.
10. Cairns, L., F.S. Rosen, and Y. Borel. 1986. Mice naturally
tolerant to C5 have T cells that suppress the response to this
antigen. Eur. J. Immunol. 16:1277–1282.
11. Lafaille, J.J., K. Nagashima, M. Katsuki, and S. Tonegawa.
1994. High incidence of spontaneous autoimmune encepha-
lomyelitis in immunodeficient anti-myelin basic protein T
cell receptor transgenic mice. Cell. 78:399–408.
12. Saoudi, A., B. Seddon, V. Heath, V. Fowell, and D. Mason.
1996. The physiological role of regulatory T cells in the pre-
vention of autoimmunity: the function of the thymus in the
generation of the regulatory T cell subset. Immunol. Rev. 149:
195–216.
13. Williams, A.F., G. Galfré, and C. Milstein. 1977. Analysis of
cell surface by xenogeneic myeloma-hybrid antibodies: dif-
ferentiation antigens of rat lymphocytes. Cell. 12:663–673.
14. McCall, M.N., D.M. Shotton, and A.N. Barclay. 1992. Ex-
pression of soluble isoforms of rat CD45. Analysis by electron
microscopy and use in epitope mapping of anti-CD45R
monoclonal antibodies. Immunology. 76:310–317.
15. Spickett, G.P., M.R. Brandon, D.W. Mason, A.F. Williams,
and G.R. Woollett. 1983. MRC OX-22, a monoclonal anti-
body that labels a new subset of T lymphocytes and reacts
with the high molecular weight form of the leukocyte-com-
mon antigen. J. Exp. Med. 158:795–810.
16. Woollett, G.R., A.N. Barclay, M. Puklavec, and A.F. Will-
iams. 1985. Molecular and antigenic heterogeneity of the rat
leukocyte-common antigen from thymocytes and T and B
lymphocytes. Eur. J. Immunol. 15:168–173.
17. Hunt, S.V., and M.H. Fowler. 1981. A repopulation assay for
B and T lymphocyte stem cells employing radiation chimae-
ras. Cell Tissue Kinetics. 14:445–464.
18. McMaster, W.R., and A.F. Williams. 1979. Identification of
Ia glycoproteins in rat thymus and purification from rat
spleen.  Eur. J. Immunol. 9:426–433.
19. Brideau, R.J., P.B. Carter, W.R. McMaster, and M. Webb.
1980. Two subsets of rat T lymphocytes defined with mono-
clonal antibodies. Eur. J. Immunol. 10:609–615.
20. Hsiung, L.M., A.N. Barclay, M.R. Brandon, E. Sim, and
R.R. Porter. 1982. Purification of human C3b inactivator by
monoclonal-antibody affinity chromatography. Biochem. J.
203:293–298.
21. Jensenius, J.C., and A.F. Williams. 1974. The binding of
anti-immunoglobulin antibodies to rat thymocytes and tho-
racic duct lymphocytes. Eur. J. Immunol. 4:91–97.
22. Gowans, J.L., and E.J. Knight. 1964. The role of re-circula-
tion of lymphocytes in the rat. Proc. R. Soc. Lond. B. Biol. Soc.
159:257–282.
23. Mason, D.W., W.J. Penhale, and J.D. Sedgwick. 1987. Prep-
aration of lymphocyte subpopulations. In Lymphocytes. 1 ed.
G.G.B. Klaus, editor. IRL Press, Oxford. 35–54.
24. Bunce, J.V., and D.W. Mason. 1981. The tolerization of rat
thymocytes to xenogeneic erythrocytes: kinetics of induction
and recovery. Eur. J. Immunol. 11:889–896.
25. Seddon, B., A. Saoudi, M. Nicholson, and D. Mason. 1996.
CD41CD8- thymocytes that express L-Selectin protect rats
from diabetes upon adoptive transfer. Eur. J. Immunol. In
press.
26. Padovan, E., G. Casorati, P. Dellabona, S. Meyer, M. Brock-
haus, and A. Lanzavecchia. 1993. Expression of two T cell
receptor alpha chains: dual receptor T cells. Science (Wash.
DC). 262:422–424.
27. Heath, W.R., and J.F. Miller. 1993. Expression of two alpha
chains on the surface of T cells in T cell receptor transgenic
mice. J. Exp. Med. 178:1807–1811.
28. Mason, D. 1994. Allelic exclusion of a chains in TCRs. Int.
Immunol. 6:881–885.
29. Le Douarin, N., C. Corbel, A. Bandeira, V. Thomas-Vaslin,
Y. Modigliani, A. Coutinho, and J. Salaün. 1996. Evidence
for a thymus-dependent form of tolerance that is not based
on elimination or anergy of reactive T cells. Immunol. Rev.
149:35–54.
30. Jolicoeur, C., D. Hanahan, and K.M. Smith. 1994. T–cell
tolerance toward a transgenic beta-cell antigen and transcrip-
tion of endogenous pancreatic genes in thymus. Proc. Natl.
Acad. Sci. USA. 91:6707–6711.
31. Fowell, D., F. Powrie, A. Saoudi, B. Seddon, V. Heath, and
D. Mason. 1995. The role of subsets of CD41 T cells in au-
toimmunity. In T Cell Subsets in Infectious and Autoim-
mune Diseases. D. Chadwick and C. Cardew, editors. John
Wiley & Sons, Ltd., Chichester, UK. 173–182.
32. Antonia, S.J., T. Geiger, J. Miller, and R.A. Flavell. 1995.
Mechanisms of immune tolerance induction through the thy-
mic expression of a peripheral tissue-specific protein. Int. Im-
munol. 7:715–725.
33. Heath, W.R., J. Allison, M.W. Hoffmann, G. Schonrich, G.
Hammerling, B. Arnold, and J.F.A.P. Miller. 1992. Autoim-
mune diabetes as a consequence of locally produced interleu-
kin-2. Nature (Lond.). 359:547–549.
34. Muir, A., A. Peck, M. Clare-Salzler, Y.H. Song, J. Cornelius,
R. Luchetta, J. Krischer, and N. Maclaren. 1995. Insulin im-
munization of nonobese diabetic mice induces a protective
insulitis characterized by diminished intraislet interferon-
gamma transcription. J. Clin. Invest. 95:628–634.
35. Parish, N.M., P.R. Hutchings, L. O’Reilly, R. Quartey-
Papafio, D. Healey, P. Ozegbe, and A. Cooke. 1995. Toler-
ance induction as a therapeutic strategy for the control of au-
toimmune endocrine disease in mouse models. Immunol. Rev.
144:269–300.
36. Morahan, G., J. Allison, and J.F.A.P. Miller. 1989. Tolerance
of class I histocompatibility antigens expressed extrathymi-
cally. Nature (Lond.). 339:622–624.
37. Powrie, F., and D. Mason. 1990. OX-22high CD41 T cells in-
duce wasting disease with multiple organ pathology: preven-
tion by the OX-22low subset. J. Exp. Med. 172:1701–1708.
38. Eishi, Y., and P. McCullagh. 1988. Acquisition of immuno-
logical self-recognition by the fetal rat. Immunology. 64:319–323.
39. Ohki, H., C. Martin, C. Corbel, M. Coltey, and N. Le
Douarin. 1987. Tolerance induced by thymic epithelium
grafts in birds. Science (Wash. DC). 237:1032–1035.
40. Kojima, A., Y. Tanaka-Kojima, T. Sakakura, and Y. Nishi-
zuka. 1976. Spontaneous development of autoimmune thy-
roiditis in neonatally thymectomized mice. Lab. Invest. 34:
550–557.
41. Taguchi, O., Y. Nishizuka, T. Sakakura, and A. Kojima.
1980. Autoimmune oophoritis in thymectomized mice: de-
tection of circulating antibodies against oocytes. Clin. Exp.
Immunol. 40:540–553.
42. Sakaguchi, S., T. Takahashi, and Y. Nishizuka. 1982. Study
on cellular events in post-thymectomy autoimmune oophor-
itis in mice. II. Requirement of Lyt-1 cells in normal female
mice for the prevention of oophoritis. J. Exp. Med. 156:
1577–1586.